Royalty Pharma Profit Margin 2019-2021 | RPRX
Current and historical gross margin, operating margin and net profit margin for Royalty Pharma (RPRX) over the last 10 years. Profit margin can be defined as the percentage of revenue that a company retains as income after the deduction of expenses. Royalty Pharma net profit margin as of March 31, 2021 is 44.35%.
|Royalty Pharma Annual Profit Margins
|Royalty Pharma Quarterly Profit Margins
||Finance - Miscellaneous Services
Royalty Pharma plc is a funder of biopharmaceutical industry. The compnay's portfolio includes royalties on commercial products, including AbbVie and J&J's Imbruvica, Astellas and Pfizer's Xtandi, Biogen's Tysabri, Gilead's HIV franchise, Merck's Januvia, Novartis' Promacta and Vertex's Kalydeco, Symdeko and Trikafta, and development-stage product candidates. Royalty Pharma plc is based in NEW YORK.